A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib - Study Drug AMN107

Project: Research project

Project Details

StatusFinished
Effective start/end date6/1/13 → 1/30/25

Funding

  • Novartis Pharmaceuticals Corporation ( Award # ): $30,429.00